Form 8.3 - Horizon Therapeutics plc

LONDON--(BUSINESS WIRE)-- 

Ap19

FORM 8.3

IRISH TAKEOVER PANEL

DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013

DEALINGS BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE

1. KEY INFORMATION

Name of person dealing (Note 1)	Millennium International Management LP
Company dealt in	Horizon Therapeutics plc
Class of relevant security to which the dealings being disclosed relate (Note 2)	IE00BQPVQZ61
Date of dealing	20^th March 2023

2. INTERESTS AND SHORT POSITIONS

a) Interests and short positions (following dealing) in the class of relevant security dealt in (Note 3)

	Long		Short
	Number	(%)	Number	(%)
(1) Relevant securities	5,539,231 (2.421%)		23,323 (0.010%)
(2) Derivatives (other than options)	-		151 (0.000%)
(3) Options and agreements to purchase/sell	105,200 (0.046%)		676,900 (0.296%)
Total	5,644,431 (2.467%)		700,374 (0.306%)

b) Interests and short positions in relevant securities of the company, other than the class dealt in (Note 3)

Class of relevant security:	Long		Short
	Number	(%)	Number	(%)
(1) Relevant securities
(2) Derivatives (other than options)
(3) Options and agreements to purchase/sell
Total

Ap20

1. DEALINGS (Note 4)

a) Purchases and sales

Purchase/sale	Number of relevant securities	Price per unit (USD) (Note 5)
Purchase	566	108.99
Sale	7,198	108.99
Purchase	100	108.97
Sale	2,816	108.97
Sale	3,035	109.04
Purchase	3,829	109.00
Sale	16,734	109.00
Sale	6,157	109.01
Sale	3,704	109.05
Sale	857	109.06
Purchase	1	108.98
Sale	2,922	108.98
Sale	3,121	109.02
Purchase	31	109.13
Sale	2,680	109.03
Sale	1,523	108.95
Sale	994	109.07
Purchase	100	108.96
Sale	2,076	108.96
Sale	953	109.08
Sale	989	108.92
Purchase	1,953	108.89
Purchase	200	108.90
Sale	8,731	108.90
Purchase	11	108.88
Purchase	300	108.84
Purchase	604	108.94
Sale	501	108.94
Sale	200	108.70
Sale	100	108.71
Sale	2,100	108.75
Sale	500	108.73
Purchase	100	108.91
Sale	2,214	108.91
Sale	100	108.69
Sale	1,046	108.93
Purchase	86	109.11
Sale	50	109.11
Sale	1,400	108.74
Purchase	33	109.09
Sale	650	109.09
Purchase	19	109.15
Purchase	11	109.16
Sale	300	108.72
Sale	13	109.25
Sale	250	108.67
Sale	100	109.10
Sale	170	108.77
Sale	630	108.76
Sale	200	108.68
Sale	143	108.66
Sale	300	108.80
Sale	23	109.04
Purchase	50	108.90
Sale	134	108.90
Sale	11	108.88
Purchase	3	108.94
Sale	6,345	108.71
Purchase	20	108.86
Purchase	5,884	108.93
Purchase	100	109.11
Purchase	46	108.78
Sale	962	108.71
Purchase	1,410	108.99
Sale	2,446	108.99
Purchase	1,868	108.97
Sale	1,597	108.97
Sale	268	109.04
Purchase	6,408	109.00
Sale	5,325	109.00
Purchase	148	109.01
Sale	2,934	109.01
Sale	300	109.05
Sale	600	109.06
Purchase	3,124	108.98
Sale	395	108.98
Sale	6,724	109.02
Purchase	42	109.13
Sale	260	109.13
Sale	1,145	109.03
Purchase	200	108.95
Sale	1,755	108.95
Sale	200	109.07
Sale	128	109.08
Sale	232	108.92
Purchase	445	108.87
Sale	922	108.87
Sale	3,787	108.89
Purchase	134	108.90
Sale	987	108.90
Purchase	180	108.88
Sale	702	108.88
Purchase	194	108.85
Sale	457	108.85
Purchase	135	108.84
Sale	401	108.84
Sale	922	108.70
Sale	8,572	108.71
Purchase	45	108.75
Sale	257	108.75
Sale	472	108.73
Purchase	161	108.86
Sale	185	108.86
Purchase	41	108.91
Sale	38	108.91
Sale	45	108.69
Sale	5,720	108.93
Sale	86	109.11
Sale	711	108.74
Purchase	377	109.12
Purchase	81	109.09
Sale	100	109.09
Sale	100	109.15
Sale	633	108.72
Sale	37	108.67
Sale	120	109.10
Sale	139	108.81
Purchase	276	108.78
Sale	100	108.78
Purchase	49	108.77
Sale	182	108.76
Sale	1,370	108.68
Sale	200	108.66
Sale	200	108.79
Sale	182	108.82
Sale	45	108.65
Purchase	400	108.71
Purchase	135	109.01

b) Derivatives transactions (other than options transactions)

Product name, e.g. CFD	Nature of transaction (Note 6)	Number of relevant securities (Note 7)	Price per unit (USD) (Note 5)
Equity Swap	Reducing a short position	44	108.88

c) Options transactions in respect of existing relevant securities

i) Writing, selling, purchasing or varying

Product name, e.g. call option	Writing, selling, purchasing, varying etc.	Number of securities to which the option relates (Note 7)	Exercise price (USD)	Type, e.g. American, European etc.	Expiry date	Option money paid/received per unit (Note 5)
Put Option	Purchasing	900	80.00	American	18/08/2023
Put Option	Purchasing	100	105.00	American	16/06/2023
Put Option	Purchasing	2,400	105.00	American	21/07/2023

ii) Exercising

Product name, e.g. call option

Number of securities

Exercise price per unit (Note 5)

d) Other dealings (including transactions in respect of new securities) (Note 4)

Nature of transaction (Note 8)

Details

Price per unit (if applicable) (Note 5)

Ap21

2. OTHER INFORMATION

Agreements, arrangements or understandings relating to options or derivatives

Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced. If none, this should be stated.

None.

Is a Supplemental Form 8 attached? (Note 9) YES

Date of disclosure	21^st March 2023
Contact name	Roisin Nagle
Telephone number	[phone]
If a connected EFM, name of offeree/offeror with which connected
If a connected EFM, state nature of connection (Note 10)

Ap32

SUPPLEMENTAL FORM 8

IRISH TAKEOVER PANEL

DISCLOSURE UNDER RULE 8.1, RULE 8.3, RULE 38.5(b) AND

RULE 38.6 OF THE IRISH TAKEOVER PANEL ACT, 1997,

TAKEOVER RULES, 2022

DETAILS OF OPEN STOCK-SETTLED DERIVATIVE (INCLUDING

OPTION) POSITIONS, AGREEMENTS TO PURCHASE OR SELL AND

RIGHTS TO SUBSCRIBE FOR NEW SECURITIES

1. KEY INFORMATION

Full name of person making disclosure:	Millennium International Management LP
Name of offeror/offeree in relation to whose relevant securities the disclosure relates:	Horizon Therapeutics plc

2. STOCK-SETTLED DERIVATIVES (INCLUDING OPTIONS)

Class of relevant security	Product description e.g. call option	Written or purchased	Number of securities to which option or derivative relates	Exercise price per unit (USD)	Type e.g. American, European etc.	Expiry date
IE00BQPVQZ61	Put Option	Purchased	1,500	90.00	American	5/19/2023
IE00BQPVQZ61	Call Option	Purchased	11,500	110.00	American	5/19/2023
IE00BQPVQZ61	Call Option	Written	366,700	115.00	American	5/19/2023
IE00BQPVQZ61	Call Option	Purchased	42,500	120.00	American	5/19/2023
IE00BQPVQZ61	Put Option	Purchased	4,300	110.00	American	5/19/2023
IE00BQPVQZ61	Put Option	Purchased	4,100	80.00	American	5/19/2023
IE00BQPVQZ61	Put Option	Purchased	400	80.00	American	1/17/2025
IE00BQPVQZ61	Put Option	Purchased	400	90.00	American	1/19/2024
IE00BQPVQZ61	Call Option	Purchased	1,200	110.00	American	8/18/2023
IE00BQPVQZ61	Call option	Written	1,200	115.00	American	8/18/2023
IE00BQPVQZ61	Put Option	Written	50,000	80.00	American	8/18/2023
IE00BQPVQZ61	Put Option	Purchased	19,800	80.00	American	8/18/2023
IE00BQPVQZ61	Put Option	Purchased	251,600	100.00	American	5/19/2023
IE00BQPVQZ61	Put Option	Purchased	5,200	105.00	American	6/16/2023
IE00BQPVQZ61	Put Option	Purchased	13,800	105.00	American	7/21/2023
IE00BQPVQZ61	Put Option	Purchased	7,900	105.00	American	4/21/2023

3. AGREEMENTS TO PURCHASE OR SELL

Full details should be given so that the nature of the interest or position can be fully understood:

Ap33

4. RIGHTS TO SUBSCRIBE FOR NEW SECURITIES (INCLUDING DIRECTORS’ AND OTHER EMPLOYEE OPTIONS)

Class of relevant security in relation to which subscription right exists:

Details, including nature of the rights concerned and relevant percentages:

It is not necessary to provide details on a Supplemental Form with regard to cash-settled derivatives.

The currency of all prices and other monetary amounts should be stated.

For full details of disclosure requirements, see Rule 8 of the Rules. If in doubt, consult the Panel.

References in these notes to “the Rules” are to the Irish Takeover Panel Act, 1997, Takeover Rules, 2022.

Category Code: RET

Sequence Number: 1076218

Time of Receipt (offset from UTC): 20230321T134231+0000